Alerts will be sent to your verified email
Verify Email
CONCORDBIO
Insufficient data
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Concord Biotech Limited, an India-based biopharmaceutical company, specializes in fermentation-based APIs for Immunosuppressants and oncology. It has a strong global presence in the US, Europe, and Japan with an expanding formulation business.
Concord Biotech major competitors are Biocon, Guj. Themis Biosyn, Advanced Enzyme, Fermenta Biotech, Alembic Pharma, Jubilant Pharmova, Caplin Point Lab.
Market Cap of Concord Biotech is ₹17,629 Crs.
While the median market cap of its peers are ₹16,028 Crs.
Concord Biotech seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | ||||||||||||||||||
| Investor Presentation | May Aug | Mar Jun Sep Dec | Jun Sep Dec | |||||||||||||||
| Conference Call | Mar Jun | Mar Jun Sep Dec | Jun Sep Dec | |||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
